Current case criteria. The firm is reviewing GLP-1 claims for sudden vision loss diagnosed as NAION only. We are not reviewing stomach or bowel injury claims, and we are not reviewing claims involving compounded semaglutide or tirzepatide. Read the NAION criteria. If that describes you or a family member, send us the details online or call (610) 255-7500.
Last updated: November 8, 2026. Siddons Law Firm reviews the status of the GLP-1 litigation each month.
The Big Picture
There are now two separate federal multidistrict litigations (MDLs) over GLP-1 drugs such as Ozempic, Wegovy, Mounjaro and Zepbound. Both are in the U.S. District Court for the Eastern District of Pennsylvania before Judge Karen S. Marston.
- MDL No. 3163 (vision loss). Claims that GLP-1 drugs caused non-arteritic anterior ischemic optic neuropathy (NAION), a sudden loss of blood flow to the optic nerve that can cause permanent vision loss. The Judicial Panel on Multidistrict Litigation created this MDL on December 15, 2025. About 278 cases were pending as of the panel’s November 2026 report.
- MDL No. 3094 (stomach and bowel injuries). Claims for gastroparesis, ileus, bowel obstruction and similar injuries. About 4,082 cases were pending as of November 2026.
Neither MDL has a global settlement. No bellwether trial dates had been set in the vision-loss cases as of the most recent public reports.
What Has Happened Recently
- The vision-loss MDL keeps growing. About 30 new cases were added each month from September through November 2026, rising from 216 to 278.
- The vision-loss cases are at an early stage. The court has been entering case-management orders and setting deadlines for plaintiff fact sheets, the questionnaires each plaintiff completes about their use of the drug and their injury.
- State court cases are moving too. Vision-loss claims are also proceeding in a New Jersey state-court multicounty litigation.
Who We Are Reviewing
We are reviewing claims from people who:
- took a brand-name GLP-1 drug such as Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Saxenda or Victoza, and
- were diagnosed with NAION after starting the drug.
We are not reviewing stomach or bowel injury claims, or claims involving compounded semaglutide or tirzepatide. See our NAION criteria for details.
Why Timing Matters
Every state sets a deadline, called a statute of limitations, for filing an injury lawsuit. The clock usually starts when you knew, or should have known, about the injury and its possible cause. If you were diagnosed with NAION after taking a GLP-1 drug, have your situation reviewed now rather than waiting for news of a settlement.
Send us the details online or call (610) 255-7500.
This post summarizes the public status of pending litigation. It is not legal advice about any specific claim. Case counts and court schedules change, so verify before relying on them.
